- Supported exchanges /
- AU /
- CMB.AU
Cambium Bio Limited (CMB AU) stock market data APIs
Regeneus Ltd, a clinical stage regenerative medicine company, develops cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain, and dermatology diseases in Australia. The company's platform technology includes Progenza, a multi-synergistic therapy, which has completed Phase I clinical trial for the treatment of osteoarthritis; and in pre-clinical stage to treat neuropathic pain. It also develops Sygenus that is in pre-clinical stage for the treatment of skin wound healing. The company was incorporated in 2007 and is headquartered in Paddington, Australia.
Cambium Bio Limited Financial Data Overview
| 0.395 | |
| 0.375 | |
| - | |
| 0.395 | |
| 0.375 | |
| 0.3-1.6 | |
| 4 713 K | |
| 306 M | |
| 988 K | |
| -0.238 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Cambium Bio Limited Fundamental Data is available in our Financial Data APIs
- Net Revenue 988 K
- EBITDA -724 595
- Earnings Per Share 0
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Cambium Bio Limited Earnings via APIs
- Latest Release 2024-08-30
- EPS/Forecast NaN
Get Cambium Bio Limited End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
